These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 35136839)
1. Global conserved RBD fraction of SARS-CoV-2 S-protein with T500S mutation in silico significantly blocks ACE2 and rejects viral spike. Banerjee A; Kanwar M; Santra D; Maiti S Transl Med Commun; 2022; 7(1):2. PubMed ID: 35136839 [TBL] [Abstract][Full Text] [Related]
2. Molecular dynamic simulation suggests stronger interaction of Omicron-spike with ACE2 than wild but weaker than Delta SARS-CoV-2 can be blocked by engineered S1-RBD fraction. Santra D; Maiti S Struct Chem; 2022; 33(5):1755-1769. PubMed ID: 35966763 [TBL] [Abstract][Full Text] [Related]
3. Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction. Nelson-Sathi S; Umasankar PK; Sreekumar E; Nair RR; Joseph I; Nori SRC; Philip JS; Prasad R; Navyasree KV; Ramesh S; Pillai H; Ghosh S; Santosh Kumar TR; Pillai MR BMC Mol Cell Biol; 2022 Jan; 23(1):2. PubMed ID: 34991443 [TBL] [Abstract][Full Text] [Related]
4. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study. Farouk AE; Baig MH; Khan MI; Park T; Alotaibi SS; Dong JJ Saudi J Biol Sci; 2021 Jun; 28(6):3262-3269. PubMed ID: 33654454 [TBL] [Abstract][Full Text] [Related]
5. Recognition through GRP78 is enhanced in the UK, South African, and Brazilian variants of SARS-CoV-2; An in silico perspective. Ibrahim IM; Elfiky AA; Elgohary AM Biochem Biophys Res Commun; 2021 Jul; 562():89-93. PubMed ID: 34049205 [TBL] [Abstract][Full Text] [Related]
6. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor. Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175 [TBL] [Abstract][Full Text] [Related]
7. Corilagin and 1,3,6-Tri- Binette V; Côté S; Haddad M; Nguyen PT; Bélanger S; Bourgault S; Ramassamy C; Gaudreault R; Mousseau N Phys Chem Chem Phys; 2021 Jul; 23(27):14873-14888. PubMed ID: 34223589 [TBL] [Abstract][Full Text] [Related]
8. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700 [TBL] [Abstract][Full Text] [Related]
9. Structural analysis of spike proteins from SARS-CoV-2 variants of concern highlighting their functional alterations. Solanki K; Rajpoot S; Kumar A; J Zhang KY; Ohishi T; Hirani N; Wadhonkar K; Patidar P; Pan Q; Baig MS Future Virol; 2022 Jul; ():. PubMed ID: 35935449 [No Abstract] [Full Text] [Related]
10. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies. Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866 [TBL] [Abstract][Full Text] [Related]
11. Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction. Cao W; Dong C; Kim S; Hou D; Tai W; Du L; Im W; Zhang XF Biophys J; 2021 Mar; 120(6):1011-1019. PubMed ID: 33607086 [TBL] [Abstract][Full Text] [Related]
12. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain. Barh D; Tiwari S; Silva Andrade B; Giovanetti M; Almeida Costa E; Kumavath R; Ghosh P; Góes-Neto A; Carlos Junior Alcantara L; Azevedo V F1000Res; 2020; 9():576. PubMed ID: 32802318 [No Abstract] [Full Text] [Related]
13. Structure-Based Virtual Screening and Identification of Potential Inhibitors of SARS-CoV-2 S-RBD and ACE2 Interaction. Xiong J; Xiang Y; Huang Z; Liu X; Wang M; Ge G; Chen H; Xu J; Zheng M; Chen L Front Chem; 2021; 9():740702. PubMed ID: 34646813 [TBL] [Abstract][Full Text] [Related]
14. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR Front Immunol; 2021; 12():691715. PubMed ID: 34149735 [TBL] [Abstract][Full Text] [Related]
15. Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity. Chakraborty S Biochem Biophys Res Commun; 2021 Jan; 534():374-380. PubMed ID: 33272568 [TBL] [Abstract][Full Text] [Related]
16. 1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection. Chen RH; Yang LJ; Hamdoun S; Chung SK; Lam CW; Zhang KX; Guo X; Xia C; Law BYK; Wong VKW Front Pharmacol; 2021; 12():634176. PubMed ID: 33897423 [TBL] [Abstract][Full Text] [Related]
17. Computational decomposition reveals reshaping of the SARS-CoV-2-ACE2 interface among viral variants expressing the N501Y mutation. Socher E; Conrad M; Heger L; Paulsen F; Sticht H; Zunke F; Arnold P J Cell Biochem; 2021 Dec; 122(12):1863-1872. PubMed ID: 34516024 [TBL] [Abstract][Full Text] [Related]
18. In Silico Comparison of Separate or Combinatorial Effects of Potential Inhibitors of the SARS-CoV-2 Binding Site of ACE2. Shakhsi-Niaei M; Soureshjani EH; Babaheydari AK Iran J Public Health; 2021 May; 50(5):1028-1036. PubMed ID: 34183961 [TBL] [Abstract][Full Text] [Related]
19. Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction. Cao W; Dong C; Kim S; Hou D; Tai W; Du L; Im W; Zhang XF bioRxiv; 2020 Jul; ():. PubMed ID: 32766576 [TBL] [Abstract][Full Text] [Related]
20. Insights into the structure and dynamics of SARS-CoV-2 spike glycoprotein double mutant L452R-E484Q. Ahamad S; Hema K; Ahmad S; Kumar V; Gupta D 3 Biotech; 2022 Apr; 12(4):87. PubMed ID: 35265451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]